Lexology June 4, 2019
Dinsmore & Shohl LLP

On May 10, 2019, the Centers for Medicare & Medicaid Services (CMS) published its final rule, 42 CFR 403, requiring drug manufacturers to disclose the price of prescription drugs in direct to consumer (DTC) advertisements. Publication of the final rule was preceded by a lively comment period that commenced on October 18, 2018. The rule is “intended to improve the efficient administration of the Medicare and Medicaid programs by ensuring that beneficiaries are provided with relevant information about the costs of prescription drugs and biological products so they can make informed decisions that minimize” costs and expenditures.

The final rule generally requires television DTC advertisements for prescription drugs and biological products to include the list price of the product. Advertisements...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: CMS, Govt Agencies, Insurance, Medicare, Pharma, Pricing / Spending, Provider, Regulations
What Fishing Can Teach Us About Lowering Healthcare Costs
Drug Expenditures Surge. Drug Prices Don't.
Weight-Loss Drugs Drive U.S. Prescription Spending
Why Are Cash Prices Lower Than Health Insurance Negotiated Prices?
STAT+: Hospital price transparency rules are seeding a new crop of health tech startups

Share This Article